The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary re

The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary re

Item

http://www.wikidata.org/entity/Q36020680

Q36020680

about

Carfilzomib boosted combination therapy for relapsed multiple myeloma Experiences of establishing an academic early phase clinical trials unit.Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma.

P2860

Q37652953-28163D85-FB4A-4BA2-93FB-38CBE0609592 Q38770579-FB58674F-6185-4F98-87B1-0903191BC76F Q50197484-E317050F-267C-42D4-A67F-178368D66387

P2860

The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary re

Item

http://www.wikidata.org/entity/Q36020680

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The MUK five protocol: a phase ...... r first relapse and primary re

@ast

The MUK five protocol: a phase ...... r first relapse and primary re

@en

The MUK five protocol: a phase ...... r first relapse and primary re

@en-gb

type

Item

label

The MUK five protocol: a phase ...... r first relapse and primary re

@ast

The MUK five protocol: a phase ...... r first relapse and primary re

@en

The MUK five protocol: a phase ...... r first relapse and primary re

@en-gb

prefLabel

The MUK five protocol: a phase ...... r first relapse and primary re

@ast

The MUK five protocol: a phase ...... r first relapse and primary re

@en

The MUK five protocol: a phase ...... r first relapse and primary re

@en-gb

P1154

2-s2.0-85013286336

http://www.w3.org/2001/XMLSchema#string

P1433

BMC hematology

P1476

The MUK five protocol: a phase ...... r first relapse and primary re

@en

P2093

Debbie Sherratt

http://www.w3.org/2001/XMLSchema#string

Eric Low

http://www.w3.org/2001/XMLSchema#string

Jamie Cavenagh

http://www.w3.org/2001/XMLSchema#string

Kwee Yong

http://www.w3.org/2001/XMLSchema#string

Louise Flanagan

http://www.w3.org/2001/XMLSchema#string

Martin Kaiser

http://www.w3.org/2001/XMLSchema#string

Myeloma UK Clinical Trials Network

http://www.w3.org/2001/XMLSchema#string

Mónica Ballesteros

http://www.w3.org/2001/XMLSchema#string

Paul McGarry

http://www.w3.org/2001/XMLSchema#string

Roger Owen

http://www.w3.org/2001/XMLSchema#string

P2860

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

P2888

s12878-016-0053-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12878-016-0053-9

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Cathy Williams

Sarah Brown

P5530

16895276

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009646190

http://www.w3.org/2001/XMLSchema#string

P6366

2403983357

http://www.w3.org/2001/XMLSchema#string

P6409

81914658

http://www.w3.org/2001/XMLSchema#string

P698

27190631

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

phase II clinical trial

P932

4869302

http://www.w3.org/2001/XMLSchema#string

P953

101993